An interventional study of Sunscreen A use in Oily Skin Aging, sponsored by Kenvue Brands LLC. Completed at 1 site in Brazil. Open to participants aged 30 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-30.
Sponsored by Kenvue Brands LLC · Not applicable, Interventional, and Basic science
This is a Single-Site, open-label, randomized clinical study that aims to evaluate the efficacy of the investigational product in improving the signs of skin aging and reducing facial oiliness in a population from 30 to 55 years of age.
Kenvue Brands LLC is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Skin Type I to VI according to Fitzpatrick's classification. For each group:
I. Fitzpatrick I and II: at least 8 participants II. Fitzpatrick III and IV: at least 8 participants III. Fitzpatrick V and VI: at least 8 participants
Participant reports, at the time of inclusion, that he/she is concerned with at least one of the following parameters related to the appearance of facial skin:
I. Fine lines II. Wrinkles III. Roughness/uneven texture
Exclusion Criteria:
Using medications that could mask an adverse event (AE) or influence the results of the study, including:
Group I: 30 participants in the age group of 30 to 44 years old, being: * At least 8 with skin type I and II on the Fitzpatrick scale * At least 8 with skin type III and IV on the Fitzpatrick scale * At least 8 with skin type V and VI on the Fitzpatrick scale
Other: Sunscreen A use
Group II: 30 participants in the age group of 45 to 55 years old, being: * At least 8 with skin type I and II on the Fitzpatrick scale * At least 8 with skin type III and IV on the Fitzpatrick scale * At least 8 with skin type V and VI on the Fitzpatrick scale
Other: Sunscreen A use
The application of the Investigational Product will be performed by the participant and supervised by a qualified technician at Visit 1 and by the participant in their home. Home use: The Investigational Product will be applied topically by the participant, following the following mode of use: "Apply an abundant amount (equivalent to one teaspoon) daily to the face and neck, at least twice a day, with reapplications whenever necessary."
Clinical efficacy of the use of Investigational Product on signs of facial aging via dermatological evaluation
It is expected to obtain statistical improvement (p≤0.05) in the evaluated attributes such as reduction of wrinkles, fine lines and roughness of the skin through the dermatological clinical evaluation of wrinkles, fine lines, and skin roughness parameters using the modified 10-point Griffith scale (from 0 to 9).
Time frame: Before and after Visit 1 (Day 0), Visit 2 (28 ± 2 days) and Visit 3 (56 ± 2 days ) of IP use
Clinical efficacy of Investigational Product in reducing skin oiliness via dermatological evaluation
It is expected to obtain statistical improvement (p≤0.05) in the evaluated attributes such as reduction of oiliness, reduction of oiliness shine, reduction of the appearance of pores through the dermatological clinical efficacy of oil shine using the modified 10-point Griffith scale (from 0 to 9).
Time frame: Before and after Visit 1 (Day 0), Visit 2 (28 ± 2 days) and Visit 3 (56 ± 2 days ) of IP use
Clinical efficacy of Investigational Product in reducing pores
It is expected to obtain statistical improvement (p≤0.05) in the evaluated attributes such as reduction of the appearance of pores through the dermatological clinical efficacy of pore appearance via modified 10-point Griffith scale (from 0 to 9).
Time frame: Before and after Visit 1 (Day 0) and Visit 3 (56 ± 2 days ) of IP use
Efficacy perceived by the participant through a questionnaire assessment
Efficacy measured by the participant through a questionnaire evaluating: * clinical efficacy of the use of Investigational Product on signs of facial aging * clinical efficacy of Investigational Product in reducing skin oiliness * clinical efficacy of Investigational Product in reducing pores
Time frame: Before and after Visit 1 (Day 0) and Visit 3 (56 ± 2 days ) of IP use
Clinical efficacy of the use of Investigational Product on signs of facial aging
Facial image captures using the COLORFACE equipment.
Time frame: Before and after Visit 1 (Day 0) and Visit 3 (56 ± 2 days ) of IP use
Clinical efficacy of the use of Investigational Product on signs of facial aging via image analysis
It is expected to obtain statistical improvement (p≤0.05) in the evaluated equipment described below: \- Evaluation of the facial images by the ANTERA 3D equipment.
Time frame: Before and after Visit 1 (Day 0), Visit 2 (28 ± 2 days) and Visit 3 (56 ± 2 days ) of IP use
Clinical efficacy of Investigational Product in reducing skin oiliness via instrumental measurements
It is expected to obtain statistical improvement (p≤0.05) in the evaluated attributes such as reduction of oiliness through the equipment below: * Instrumental measurements with the Sebumeter® equipment.
Time frame: Before and after Visit 1 (Day 0), Visit 2 (28 ± 2 days) and Visit 3 (56 ± 2 days ) of IP use
The clinical efficacy of Investigational Product in maintaining skin hydration
It is expected to obtain statistical improvement (p≤0.05) in the evaluated attributes, such as skin hydration through the equipment and evaluations described below: \- To evaluate the clinical efficacy of Investigational Product in maintaining skin hydration, by measurements with Corneometer® equipment.
Time frame: Before and after Visit 1 (Day 0) and Visit 3 (56 ± 2 days ) of IP use
The clinical efficacy of Investigational Product in maintaining the skin barrier
It is expected to obtain statistical improvement (p≤0.05) in the evaluated attributes, such as reduction and/or maintenance of trans epidermal water loss through the equipment and evaluations described below: \- To evaluate the clinical efficacy of Investigational Product in maintaining trans epidermal water loss with Tewameter equipment.
Time frame: Before and after Visit 1 (Day 0) and Visit 3 (56 ± 2 days ) of IP use
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kenvue Brands LLC